OrbiMed Advisors
Latest statistics and disclosures from Orbimed Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are Sinovac Biotech, EWTX, BSX, LLY, ELVN, and represent 32.97% of Orbimed Advisors's stock portfolio.
- Added to shares of these 10 stocks: PFE (+$104M), AXSM (+$45M), Sionna Therapeutics (+$39M), UNH (+$37M), TARS (+$34M), APLS (+$31M), EW (+$28M), CGON (+$26M), TMO (+$22M), RNA (+$21M).
- Started 10 new stock positions in TARS, Sionna Therapeutics, Aadi Bioscience, Kestra Med Technologie F, AXSM, APLS, ORIC, TRVI, DHAI, AMGN.
- Reduced shares in these 10 stocks: SRPT (-$117M), , , UHS (-$57M), ISRG (-$55M), THC (-$47M), BSX (-$35M), GILD (-$28M), XBI (-$22M), MLYS (-$20M).
- Sold out of its positions in ARDT, BIIB, ELEV, GERN, IMVT, ITCI, LYEL, MEDP, MRK, MIST. MLYS, NMRA, PEPG, SRPT, UHS.
- Orbimed Advisors was a net seller of stock by $-190M.
- Orbimed Advisors has $4.2B in assets under management (AUM), dropping by -13.69%.
- Central Index Key (CIK): 0001055951
Tip: Access up to 7 years of quarterly data
Positions held by OrbiMed Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Orbimed Advisors
Orbimed Advisors holds 107 positions in its portfolio as reported in the March 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Sinovac Biotech SHS | 8.0 | $334M | 2.7M | 122.85 |
|
|
| Edgewise Therapeutics (EWTX) | 7.9 | $331M | 15M | 22.00 |
|
|
| Boston Scientific Corporation (BSX) | 6.8 | $284M | -10% | 2.8M | 100.88 |
|
| Eli Lilly & Co. (LLY) | 6.6 | $279M | 338k | 825.91 |
|
|
| Enliven Therapeutics (ELVN) | 3.7 | $157M | 8.0M | 19.68 |
|
|
| Intuitive Surgical Com New (ISRG) | 3.4 | $144M | -27% | 291k | 495.27 |
|
| Stryker Corporation (SYK) | 3.2 | $134M | +4% | 359k | 372.25 |
|
| Argenx Se Sponsored Adr (ARGX) | 2.9 | $122M | +8% | 207k | 591.87 |
|
| Edwards Lifesciences (EW) | 2.6 | $111M | +33% | 1.5M | 72.48 |
|
| Pfizer (PFE) | 2.6 | $110M | +1640% | 4.4M | 25.34 |
|
| UnitedHealth (UNH) | 2.5 | $105M | +53% | 201k | 523.75 |
|
| Silverback Therapeutics (SPRY) | 2.5 | $104M | 8.3M | 12.58 |
|
|
| Neurocrine Biosciences (NBIX) | 2.5 | $103M | 935k | 110.60 |
|
|
| Alnylam Pharmaceuticals (ALNY) | 2.2 | $94M | -16% | 346k | 270.02 |
|
| Integer Hldgs (ITGR) | 1.9 | $78M | +15% | 663k | 118.01 |
|
| Vertex Pharmaceuticals Incorporated (VRTX) | 1.8 | $78M | +5% | 160k | 484.82 |
|
| Natera (NTRA) | 1.8 | $77M | +32% | 547k | 141.41 |
|
| Ionis Pharmaceuticals (IONS) | 1.8 | $77M | -9% | 2.5M | 30.17 |
|
| Disc Medicine (IRON) | 1.7 | $70M | -20% | 1.4M | 49.64 |
|
| Thermo Fisher Scientific (TMO) | 1.5 | $64M | +52% | 129k | 497.60 |
|
| Tenet Healthcare Corp Com New (THC) | 1.5 | $63M | -43% | 465k | 134.50 |
|
| Cytokinetics Com New (CYTK) | 1.4 | $61M | -4% | 1.5M | 40.19 |
|
| Cg Oncology (CGON) | 1.4 | $61M | +72% | 2.5M | 24.49 |
|
| Arrivent Biopharma (AVBP) | 1.3 | $56M | 3.0M | 18.49 |
|
|
| Avidity Biosciences Ord (RNA) | 1.3 | $54M | +62% | 1.8M | 29.52 |
|
| Springworks Therapeutics (SWTX) | 1.2 | $50M | -10% | 1.1M | 44.13 |
|
| Si-bone (SIBN) | 1.2 | $48M | -6% | 3.4M | 14.03 |
|
| Axsome Therapeutics (AXSM) | 1.1 | $45M | NEW | 387k | 116.63 |
|
| Compass Therapeutics (CMPX) | 1.0 | $43M | 22M | 1.90 |
|
|
| Neuropace (NPCE) | 1.0 | $42M | 3.4M | 12.29 |
|
|
| Sionna Therapeutics | 0.9 | $39M | NEW | 3.7M | 10.46 |
|
| Upstream Bio (UPB) | 0.8 | $35M | 5.7M | 6.12 |
|
|
| Xtant Med Hldgs Com New (XTNT) | 0.8 | $34M | 73M | 0.47 |
|
|
| Tarsus Pharmaceuticals (TARS) | 0.8 | $34M | NEW | 654k | 51.37 |
|
| Crinetics Pharmaceuticals In (CRNX) | 0.8 | $34M | 999k | 33.54 |
|
|
| Xenon Pharmaceuticals (XENE) | 0.8 | $32M | 948k | 33.55 |
|
|
| Apellis Pharmaceuticals (APLS) | 0.7 | $31M | NEW | 1.4M | 21.87 |
|
| Mbx Biosciences (MBX) | 0.7 | $30M | +5% | 4.0M | 7.38 |
|
| EXACT Sciences Corporation (EXAS) | 0.7 | $29M | 680k | 43.29 |
|
|
| Gilead Sciences (GILD) | 0.5 | $22M | -55% | 198k | 112.05 |
|
| Corvus Pharmaceuticals (CRVS) | 0.5 | $22M | 6.9M | 3.18 |
|
|
| Terns Pharmaceuticals (TERN) | 0.5 | $21M | 7.6M | 2.76 |
|
|
| Janux Therapeutics (JANX) | 0.5 | $21M | 759k | 27.00 |
|
|
| Rhythm Pharmaceuticals (RYTM) | 0.5 | $20M | -5% | 380k | 52.97 |
|
| Third Harmonic Bio (THRD) | 0.5 | $20M | 5.8M | 3.47 |
|
|
| Amicus Therapeutics (FOLD) | 0.4 | $19M | 2.3M | 8.16 |
|
|
| Verastem Com New (VSTM) | 0.4 | $17M | 2.9M | 6.03 |
|
|
| Tyra Biosciences (TYRA) | 0.4 | $16M | +19% | 1.8M | 9.30 |
|
| Rapt Therapeutics (RAPT) | 0.4 | $16M | 13M | 1.22 |
|
|
| Scpharmaceuticals (SCPH) | 0.4 | $16M | 6.1M | 2.63 |
|
|
| Ikena Oncology Nonvoting | 0.4 | $15M | 12M | 1.28 |
|
|
| Vir Biotechnology (VIR) | 0.3 | $15M | -30% | 2.2M | 6.48 |
|
| Cullinan Oncology (CGEM) | 0.3 | $15M | 1.9M | 7.57 |
|
|
| Immatics SHS (IMTX) | 0.3 | $14M | 3.1M | 4.51 |
|
|
| Structure Therapeutics Sponsored Ads (GPCR) | 0.3 | $14M | 802k | 17.31 |
|
|
| Amgen (AMGN) | 0.3 | $14M | NEW | 44k | 311.55 |
|
| Vera Therapeutics Cl A (VERA) | 0.3 | $12M | -35% | 481k | 24.02 |
|
| C4 Therapeutics Com Stk (CCCC) | 0.3 | $11M | +50% | 6.8M | 1.60 |
|
| Dyne Therapeutics (DYN) | 0.3 | $11M | -17% | 1.0M | 10.46 |
|
| Keros Therapeutics (KROS) | 0.2 | $10M | 1.0M | 10.19 |
|
|
| Acelyrin (SLRN) | 0.2 | $9.9M | 4.0M | 2.47 |
|
|
| Agios Pharmaceuticals (AGIO) | 0.2 | $9.5M | +1119% | 326k | 29.30 |
|
| Abcellera Biologics (ABCL) | 0.2 | $9.3M | 4.2M | 2.23 |
|
|
| Adicet Bio (ACET) | 0.2 | $8.6M | 11M | 0.76 |
|
|
| Adc Therapeutics Sa SHS (ADCT) | 0.2 | $8.4M | 6.0M | 1.41 |
|
|
| Prelude Therapeutics (PRLD) | 0.2 | $8.4M | 11M | 0.77 |
|
|
| Spdr Ser Tr S&p Biotech Call Option (XBI) | 0.2 | $8.1M | -73% | 100k | 81.10 |
|
| Avalo Therapeutics Com New (AVTX) | 0.2 | $7.7M | 967k | 8.01 |
|
|
| Aadi Bioscience | 0.2 | $7.4M | NEW | 4.2M | 1.78 |
|
| Akero Therapeutics (AKRO) | 0.2 | $7.3M | +172% | 180k | 40.48 |
|
| Pmv Pharmaceuticals (PMVP) | 0.2 | $7.1M | 6.5M | 1.09 |
|
|
| Trevi Therapeutics (TRVI) | 0.2 | $7.0M | NEW | 1.1M | 6.29 |
|
| Kestra Med Technologies SHS | 0.1 | $6.2M | NEW | 250k | 24.92 |
|
| Corbus Pharmaceuticals Hldgs Com New (CRBP) | 0.1 | $6.2M | 1.2M | 5.31 |
|
|
| Inspiremd (NSPR) | 0.1 | $5.7M | 2.1M | 2.69 |
|
|
| Scholar Rock Hldg Corp (SRRK) | 0.1 | $4.9M | 152k | 32.15 |
|
|
| Forte Biosciences Com New (FBRX) | 0.1 | $4.6M | 593k | 7.76 |
|
|
| Ikena Oncology (IKNA) | 0.1 | $4.5M | 3.5M | 1.28 |
|
|
| Krystal Biotech (KRYS) | 0.1 | $4.2M | 24k | 180.30 |
|
|
| Engene Holdings (ENGN) | 0.1 | $4.0M | -3% | 892k | 4.48 |
|
| Oric Pharmaceuticals (ORIC) | 0.1 | $3.9M | NEW | 700k | 5.58 |
|
| Bicara Therapeutics (BCAX) | 0.1 | $3.9M | 298k | 13.03 |
|
|
| Q32 Bio (QTTB) | 0.1 | $3.7M | 2.3M | 1.65 |
|
|
| Bioage Labs (BIOA) | 0.1 | $3.5M | 922k | 3.76 |
|
|
| Repare Therapeutics Ord (RPTX) | 0.1 | $3.3M | 3.3M | 0.99 |
|
|
| Passage Bio (PASG) | 0.1 | $2.5M | -4% | 7.0M | 0.35 |
|
| Insmed Com Par $.01 (INSM) | 0.1 | $2.2M | -69% | 29k | 76.29 |
|
| Ceribell (CBLL) | 0.1 | $2.2M | 113k | 19.21 |
|
|
| Instil Bio Com New (TIL) | 0.0 | $2.0M | 117k | 17.36 |
|
|
| Chemomab Therapeutics Sponsored Ads (CMMB) | 0.0 | $1.9M | 1.7M | 1.09 |
|
|
| Cardiff Oncology (CRDF) | 0.0 | $1.8M | -62% | 574k | 3.14 |
|
| X4 Pharmaceuticals (XFOR) | 0.0 | $1.6M | -5% | 6.8M | 0.24 |
|
| Nkarta (NKTX) | 0.0 | $1.5M | 821k | 1.84 |
|
|
| Traws Pharma Com New (TRAW) | 0.0 | $1.4M | 606k | 2.30 |
|
|
| Fate Therapeutics (FATE) | 0.0 | $1.3M | 1.7M | 0.79 |
|
|
| Turnstone Biologics Corp (TSBX) | 0.0 | $1.3M | 3.1M | 0.41 |
|
|
| Amylyx Pharmaceuticals (AMLX) | 0.0 | $1.2M | 348k | 3.54 |
|
|
| Biomx Com New (PHGE) | 0.0 | $994k | 1.8M | 0.56 |
|
|
| Kezar Life Sciences Com New (KZR) | 0.0 | $940k | 193k | 4.88 |
|
|
| Tango Therapeutics (TNGX) | 0.0 | $754k | 550k | 1.37 |
|
|
| Adagio Therapeutics (IVVD) | 0.0 | $565k | -18% | 934k | 0.61 |
|
| Korro Bio (KRRO) | 0.0 | $564k | 32k | 17.41 |
|
|
| Nextcure (NXTC) | 0.0 | $548k | 1.1M | 0.48 |
|
|
| Alto Neuroscience Com Shs (ANRO) | 0.0 | $540k | 250k | 2.16 |
|
|
| Dih Hldg Us Cl A (DHAI) | 0.0 | $443k | NEW | 1.9M | 0.23 |
|
| Xeris Pharmaceuticals (XERS) | 0.0 | $442k | 80k | 5.49 |
|
|
| Lakeshore Biopharma Ord Shs New (LSB) | 0.0 | $344k | 140k | 2.45 |
|
Past Filings by Orbimed Advisors
SEC 13F filings are viewable for Orbimed Advisors going back to 2010
- Orbimed Advisors 2025 Q1 filed May 15, 2025
- Orbimed Advisors 2024 Q4 filed Feb. 14, 2025
- Orbimed Advisors 2024 Q3 filed Nov. 14, 2024
- Orbimed Advisors 2024 Q2 filed Aug. 14, 2024
- Orbimed Advisors 2024 Q1 filed May 15, 2024
- Orbimed Advisors 2023 Q4 filed Feb. 14, 2024
- Orbimed Advisors 2023 Q3 filed Nov. 14, 2023
- Orbimed Advisors 2023 Q2 filed Aug. 14, 2023
- Orbimed Advisors 2023 Q1 filed May 15, 2023
- Orbimed Advisors 2022 Q4 filed Feb. 14, 2023
- Orbimed Advisors 2022 Q3 filed Nov. 14, 2022
- Orbimed Advisors 2022 Q2 filed Aug. 15, 2022
- Orbimed Advisors 2022 Q1 filed May 16, 2022
- Orbimed Advisors 2021 Q4 filed Feb. 14, 2022
- Orbimed Advisors 2021 Q3 filed Nov. 15, 2021
- Orbimed Advisors 2021 Q2 filed Aug. 16, 2021